Cognitive behaviour therapy tailored to migraine in multiple sclerosis: A pilot randomized controlled trial
Abstract
ABSTRACT Approximately 50% of people with relapsing-remitting multiple sclerosis (RRMS) have comorbid migraine. This pilot randomized controlled trial examined the feasibility and preliminary efficacy of a five-week cognitive behaviour therapy targeted to treating migraine in RRMS (CBT-MMS). Participants with RRMS and ≥3 migraine days per month (MMD) received CBT-MMS or a nine-week waitlist. Feasibility was assessed by rates of retention, follow-up and outcome responses. Candidate primary outcomes were MMD, migraine duration, and pain intensity at baseline, post-treatment, and one-month follow-up. Secondary outcomes included mood, fatigue, self-efficacy, pain catastrophizing, disability and quality of life. Data were analyzed through multilevel modelling. Participants were 31 adults aged 22–59 with 8.32 ± 6.12 MMD at baseline. The retention rate was 96.77%. From baseline, the CBT-MMS group (n=21) had significantly fewer MMD and shorter migraine duration (in hours) at post-treatment (EMM=3.05 days, 95%CI [−5.32, −2.13]; EMM=6.34 h, 95%CI [−10.62, −5.15], respectively) and follow-up (EMM=2.82 days, 95%CI [−5.58, −2.33]; EMM=7.20 h, 95%CI [−9.64, −4.39], respectively). The waitlist group (n=10) had no such within-group changes. Treatment gains were found for anxiety, self-efficacy, and migraine-related disability, and no effects were found on remaining outcomes. These findings provide preliminary support for the feasibility and efficacy potential of CBT-MMS, warranting a…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 31 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.